Dipeptidyl peptidase I (cathepsin C)

- a novel target for the treatment of inflammatory diseases

 

UNIZYME Laboratories is a virtual Danish biotech company focused on design and development of novel small molecule inhibitors of dipeptidyl peptidase I (DPPI; also known as cathepsin C) for treatment of inflammatory diseases.

 

DPPI is an activator of neutrophil elastase (NE), cathepsin G (catG) and proteinase 3 (Pr3) known to be involved in a vast variety of inflammatory condition and a validated drug target for a number of chronic diseases with components of neutrophil inflammation, such as COPD, cystic fibrosis, alpha-1 antitrypsin deficiency, rheumatoid arthritis and gout.